Study on efficacy-enhancing and toxicity-reducing of different rhubarb processed products combined with atorvastatin / 中草药

ABSTRACT

Objective: To explore the effect of different processed products of rhubarb combined with atorvastatin (ATS) on the efficacy-enhancing and toxicity-reducing. Methods: L02 cells were used to investigate the hepatoprotective effects of raw rhubarb, wine-fried rhubarb and wine-steamed rhubarb in clinical application combined with ATS, and the extracts of the processed products with the best liver protection were screened out. The effective lipid-lowering dose range of the extract of the processed product was determined by HepG2 cell experiments; Finally, based on the model of hyperlipidemia in SD rats, the lipid-lowering and hepatoprotective effects of the optimal extract and ATS were generally evaluated by measuring the blood lipid and transaminase levels and related oxidative stress parameters, detecting the histopathological section of the liver. Results: The alcohol extract of wine-fried rhubarb in the three processed artillery products significantly improved the survival rate of L02 cells, and had the best protection effect on L02 cells induced by ATS. At the same time, the wine-fried rhubarb ethanol extract also effectively reduced the content of TC and TG in HepG2 hepatic steatosis cells. The liver-protection ratio and lipid-lowering ratio (mass ratio) of ATS to wine-fried rhubarb ethanol extract were 16.7-19.0 and 135.8-171.6. The wine-fried rhubarb ethanol extract and ATS reduced the blood lipid level and lipid content in the liver of hyperlipidemia rats; The serum levels of ALT and AST were significantly decreased, the SOD activity in the liver was significantly enhanced, and the MDA content was significantly reduced; And high-dose wine-fried rhubarb ethanol extract and ATS combination group significantly inhibited inflammatory cell infiltration and bile duct hyperplasia. Conclusion: The combination of wine-fried rhubarb ethanol extract and ATS can significantly improve the liver function damage caused by ATS, enhance the effect of lipid-lowering therapy on hyperlipidemic rats, and play a role in reducing toxicity and increasing efficiency.